Effects of Weight Loss Interventions on Gut Microbiota-Derived Metabolites Linked to Cardiometabolic Health: A Systematic Review and Meta-Analysis.

Obes RevApr 28, 2026 (epub)

Fernando Q Iorra, Leonardo André Swarowsky Loebens, Andrea Auler et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis assessed how weight-loss interventions affect circulating gut microbiota-derived metabolites in people with overweight or obesity. Across 67 studies, non-surgical interventions were associated with lower TMAO (SMD: -0.56; 95% CI -0.90 to -0.22), but not LPS. Surgical interventions were associated with lower LPS (SMD: -0.47; 95% CI -0.80 to -0.14) and higher TMAO and secondary bile acids. Evidence for short-chain fatty acids and indole derivatives was limited, and the findings differed by intervention type.

Key findings

  • Non-surgical interventions were associated with reduced TMAO (SMD: -0.56; 95% CI -0.90 to -0.22; I 2 = 74.7%).
  • Non-surgical interventions were not associated with a clear change in LPS (SMD: -0.11; 95% CI -0.58 to 0.35).
  • Surgical interventions were associated with decreased LPS (SMD: -0.47; 95% CI -0.80 to -0.14) and increased TMAO (SMD: 0.49; 95% CI 0.08 to 0.90).
  • Surgical interventions were associated with increased secondary bile acids (SMD: 0.48; 95% CI 0.30 to 0.66); evidence for SCFAs and indole derivatives was limited.

Why it matters

The differing metabolite patterns suggest that weight loss does not produce a uniform change in circulating microbial products. These findings add context to the complex relationship between obesity, gut microbiota and cardiometabolic health, while highlighting that metabolite responses may vary with intervention type. The clinical significance of these changes is not established by the reported results.

What to keep in mind

Heterogeneity was substantial for several pooled outcomes, including TMAO and LPS, and evidence for SCFAs and indole derivatives was limited.

Source

Published in Obes Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.